Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More
Elanco opened the doors of its new headquarters at the former GM stamping plant site this week.
Read More
As chief operating officer, Severns oversees 14 offices at 11 sites, including the new Carmel facility on Illinois Street, that treat roughly 900 patients a day.
Read More
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that limits choice.
An Elanco spokeswoman said cuts to the company’s Indiana workforce are “very minimal.” Most of the eliminated positions are from the company’s planned closure of its German R&D facility.
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Yet promising health tech companies still leave the state to raise growth capital.
Indianapolis-based Roche Diagnostics said while the survey was conducted in Europe, its implications are global and reflect challenges in the United States.
Dr. Michael Meneghini waited out a two-year noncompete clause after leaving Indiana University Health before opening the $35 million Indiana Orthopedic Institute early this year.
Indianapolis-based Alloy Partners says its OneHealth Studio, a venture studio that quietly began operating last month in partnership with Elanco Animal Health Inc., will be ready to create its first startups early next year.
Despite reporting a loss, the company saw quarterly growth in the double digits and raised its full-year earnings estimate.
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
Purdue University’s new Center for Musculoskeletal Engineering in Indianapolis has a growth plan that metaphorically matches a healthy growing body.
Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.
The relocated jobs would pay an average wage of $40.71 an hour, and the new jobs would pay an average wage of $45.90, according to town documents.
The Lebanon-based hospital faces increased competition from large health systems that benefit from larger economies of scale and marketing budgets.
The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.
Indiana’s hospital systems could face hundreds of millions of dollars in annual Medicaid reimbursement cuts if the rates they charge to employer-provided insurance plans are higher than thresholds set by Gov. Mike Braun’s administration.
